相似文献
1
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization.
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10193-8. doi: 10.1073/pnas.0608635104. Epub 2007 May 31.
2
Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
AIDS Res Hum Retroviruses. 2005 Jan;21(1):58-67. doi: 10.1089/aid.2005.21.58.
3
HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Vaccine. 2006 Jun 29;24(26):5442-51. doi: 10.1016/j.vaccine.2006.03.063. Epub 2006 Apr 3.
4
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
J Virol. 2006 Feb;80(3):1414-26. doi: 10.1128/JVI.80.3.1414-1426.2006.
5
Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.
PLoS One. 2014 May 20;9(5):e98060. doi: 10.1371/journal.pone.0098060. eCollection 2014.
6
Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
Virology. 2007 Jun 20;363(1):79-90. doi: 10.1016/j.virol.2007.01.015. Epub 2007 Feb 15.
7
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
J Virol. 2003 Mar;77(5):3119-30. doi: 10.1128/jvi.77.5.3119-3130.2003.
8
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
J Virol. 2001 Jan;75(2):645-53. doi: 10.1128/JVI.75.2.645-653.2001.
9
Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
J Virol. 2006 Sep;80(17):8745-62. doi: 10.1128/JVI.00956-06.
10
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
J Virol. 1998 Dec;72(12):9656-67. doi: 10.1128/JVI.72.12.9656-9667.1998.
引用本文的文献
1
The wide utility of rabbits as models of human diseases.
Exp Mol Med. 2018 May 22;50(5):1-10. doi: 10.1038/s12276-018-0094-1.
2
Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response.
PLoS One. 2016 Jun 14;11(6):e0157353. doi: 10.1371/journal.pone.0157353. eCollection 2016.
3
Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.
J Virol. 2016 Apr 14;90(9):4481-4493. doi: 10.1128/JVI.03206-15. Print 2016 May.
4
Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs.
J Virol. 2015 Oct;89(20):10707-11. doi: 10.1128/JVI.01642-15. Epub 2015 Aug 5.
5
Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.
PLoS One. 2014 May 20;9(5):e98060. doi: 10.1371/journal.pone.0098060. eCollection 2014.
6
Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.
PLoS One. 2014 Jan 23;9(1):e86905. doi: 10.1371/journal.pone.0086905. eCollection 2014.
7
Allosteric induction of the CD4-bound conformation of HIV-1 Gp120.
Retrovirology. 2013 Dec 5;10:147. doi: 10.1186/1742-4690-10-147.
8
Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein.
PLoS One. 2013 Oct 16;8(10):e76139. doi: 10.1371/journal.pone.0076139. eCollection 2013.
9
Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
PLoS One. 2013 Oct 1;8(10):e78521. doi: 10.1371/journal.pone.0078521. eCollection 2013.
10
Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.
J Transl Med. 2013 Jul 8;11:165. doi: 10.1186/1479-5876-11-165.
本文引用的文献
1
Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.
J Virol. 2006 Dec;80(23):11776-90. doi: 10.1128/JVI.01730-06. Epub 2006 Sep 13.
2
GP120: target for neutralizing HIV-1 antibodies.
Annu Rev Immunol. 2006;24:739-69. doi: 10.1146/annurev.immunol.24.021605.090557.
3
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
J Virol. 2006 Feb;80(3):1414-26. doi: 10.1128/JVI.80.3.1414-1426.2006.
4
Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
Virology. 2006 Mar 30;347(1):36-51. doi: 10.1016/j.virol.2005.11.019. Epub 2005 Dec 27.
5
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
J Virol. 2005 Aug;79(16):10108-25. doi: 10.1128/JVI.79.16.10108-10125.2005.
6
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.
J Virol. 2005 Aug;79(16):10103-7. doi: 10.1128/JVI.79.16.10103-10107.2005.
7
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
Vaccine. 2005 Aug 15;23(35):4442-52. doi: 10.1016/j.vaccine.2005.03.042.
8
HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity.
Virology. 2005 Sep 1;339(2):226-38. doi: 10.1016/j.virol.2005.06.003.
9
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
J Virol. 2005 Mar;79(6):3358-69. doi: 10.1128/JVI.79.6.3358-3369.2005.
10
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27.
Zotero 插件